No­var­tis con­tin­ues its blitz on NASH deals, grab­bing an ex­clu­sive tie-up in race to de­vel­op cock­tails

Five months ago No­var­tis $NVS rocked Cona­tus’ world with a col­lab­o­ra­tion deal for its NASH drug em­ri­c­as­an. The biotech’s stock quadru­pled in val­ue. And it got an­oth­er boost to­day as the phar­ma gi­ant fol­lowed up with its an­nounce­ment that it is in­deed pick­ing up the ex­clu­sive world­wide op­tion for the drug, chip­ping in an ex­tra $7 mil­lion to seal the deal.

Cona­tus stock $CNAT is up 13% in pre-mar­ket trad­ing and the mi­cro biotech has seen its mar­ket cap break through the $200 mil­lion mark.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER